Adjuvant treatment with vindesine in comparison to observation alone in patients with metastasized melanoma after complete metastasectomy: A randomized multicenter trial of the German Dermatologic Cooperative Oncology Group

Melanoma Research

Volumn 18, Issue 5, 2008, Pages 353-358

  Eigentler, Thomas K ^a   Radny, Peter ^a   Hauschild, Axel ^b   Gutzmer, Ralf ^c   Linse, Ruthild ^d   Pföhler, Claudia ^e   Wagner, Stephan N ^g   Schadendorf, Dirk ^f   Ellwanger, Ulf ^a   Garbe, Claus ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF KIEL   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d HELIOS KLINIKUM ERFURT   (Germany)

^e SAARLAND UNIVERSITY   (Germany)

^f UNIVERSITY OF HEIDELBERG   (Germany)

^g MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Adjuvant; Metastatic melanoma; Randomized trial; Vindesine

Indexed keywords

VINDESINE;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER SURGERY; CANCER SURVIVAL; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FEVER; FOLLOW UP; GERMANY; GRANULOCYTOPENIA; HIGH RISK PATIENT; HUMAN; INFECTION; INTERMETHOD COMPARISON; LEUKOPENIA; LONG TERM CARE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASECTOMY; MULTICENTER STUDY; NEUTROPENIA; OBSERVATIONAL METHOD; OVERALL SURVIVAL; PAIN; PERIPHERAL NEUROPATHY; POSTOPERATIVE CARE; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RASH; REGIONAL METASTASIS; SIDE EFFECT; SURVIVAL RATE; THROMBOCYTOPENIA;

ADULT; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; SKIN NEOPLASMS; SURVIVAL RATE; VINDESINE;

EID: 53549105257     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/CMR.0b013e32830e3936     Document Type: Article

References (18)

1. Eigentler TK, Caroli UM, Radny P, Garbe C. Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol 2003; 4:748-759.
2. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19:3635-3648.
3. Grob JJ, Dreno B, De la SP, Delaunay M, Cupissol D, Guillot B, et al. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet 1998; 351:1905-1910.
4. Hancock BW, Wheatley K, Harris S, Ives N, Harrison G, Horsman JM, et al. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study-United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma. J Clin Oncol 2004; 22:53-61.
5. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol1996; 14:7-17
6. Kirkwood JM, Ibrahim JG, Sondak VK, Richards J, Flaherty LE, Ernstoff MS, et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111 /C9190. J Clin Oncol 2000; 18:2444-2458.
7. Pehamberger H, Soyer HP, Steiner A, Kofler R, Binder M, Mischer R et al. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J Clin Oncol 1998; 16:1425-1429.
8. Wheatley K, Ives N, Hancock B, Gore M, Eggermont A, Suciu S. Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat Rev 2003; 29:241-252.
9. Garbe C, Eigentler TK. Diagnosis and treatment of cutaneous melanoma: state of the art 2006. Melanoma Res 2007; 17:117-127.
10. Cascinelli N, Belli F, MacKie RM, Santinami M, Bufalino R, Morabito A. Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial. Lancet 2001; 358:866~869.
11. Kirkwood JM, Manola J, Ibrahim J, Sondak V, Ernstoff MS, Rao U. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 2004; 10:1670-1677.
12. Retsas S, Quigley M, Pectasides D, Macrae K, Henry K. Clinical and histologic involvement of regional lymph nodes in malignant melanoma. Adjuvant vindesine improves survival. Cancer 1994; 73:2119-2130.
13. World Health Organization. WHO Handbook for reporting results of cancer treatment. Geneva: World Health Organization Offset Publication; 1979.
14. Moher D. CONSORT: an evolving tool to help improve the quality of reports of randomized controlled trials. Consolidated Standards of Reporting Trials. J Am Med Assoc 1998; 279:1489-1491.
15. Veronesi U, Adamus J, Aubert C, Bajetta E, Beretta G, Bonadonna G, et al. A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. N Engl J Med 1982; 307:913-916.
16. Balch CM, Murray D, Presant C, Bartolucci AA. Ineffectiveness of adjuvant chemotherapy using DTIC and cyclophosphamide in patients with resectable metastatic melanoma. Surgery 1984; 95: 454-459.
17. Hill GJ, Moss SE, Golomb FM, Grage TB, Fletcher WS, Minton JP, Krementz ET. DTIC and combination therapy for melanoma: III. DTIC (NSC 45388) Surgical Adjuvant Study COG PROTOCOL 7040. Cancer 1981; 47: 2556-2562.
18. Karakousis C, Blumenson L Adjuvant chemotherapy with a nitrosourea-based protocol in advanced malignant melanoma. Eur J Cancer 1993; 29A;1831-1835.